loading
Schlusskurs vom Vortag:
$127.12
Offen:
$127.22
24-Stunden-Volumen:
1.56M
Relative Volume:
0.71
Marktkapitalisierung:
$13.55B
Einnahmen:
$612.78M
Nettoeinkommen (Verlust:
$-86.37M
KGV:
-146.62
EPS:
-0.87
Netto-Cashflow:
$-62.91M
1W Leistung:
+0.52%
1M Leistung:
+34.46%
6M Leistung:
+73.29%
1J Leistung:
+75.29%
1-Tages-Spanne:
Value
$127.06
$127.97
1-Wochen-Bereich:
Value
$126.92
$127.97
52-Wochen-Spanne:
Value
$62.78
$128.00

Intra Cellular Therapies Inc Stock (ITCI) Company Profile

Name
Firmenname
Intra Cellular Therapies Inc
Name
Telefon
(646) 440-9333
Name
Adresse
135 ROUTE 202/206, BEDMINSTER, NY
Name
Mitarbeiter
561
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
ITCI's Discussions on Twitter

Vergleichen Sie ITCI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
ITCI
Intra Cellular Therapies Inc
127.56 13.55B 612.78M -86.37M -62.91M -0.87
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
174.29 78.63B 9.15B 2.43B 2.31B 5.32
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.85 44.54B 14.26B 1.55B 0 0.3383
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.44 42.61B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.59 18.79B 16.54B -1.64B 749.00M -1.45

Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-31 Herabstufung Canaccord Genuity Buy → Hold
2024-09-06 Hochstufung Piper Sandler Neutral → Overweight
2024-01-03 Eingeleitet Robert W. Baird Outperform
2023-12-11 Eingeleitet TD Cowen Outperform
2023-04-20 Eingeleitet Morgan Stanley Overweight
2022-08-22 Herabstufung Goldman Buy → Neutral
2022-07-07 Eingeleitet Mizuho Buy
2022-06-14 Eingeleitet UBS Buy
2022-04-22 Eingeleitet Piper Sandler Neutral
2022-02-16 Eingeleitet Goldman Buy
2021-09-23 Eingeleitet Needham Buy
2020-12-15 Eingeleitet BofA Securities Buy
2020-12-10 Eingeleitet Goldman Buy
2020-02-20 Eingeleitet Evercore ISI Outperform
2020-01-31 Herabstufung JP Morgan Overweight → Neutral
2019-12-24 Bestätigt Canaccord Genuity Buy
2019-08-12 Eingeleitet Jefferies Buy
2018-02-26 Eingeleitet JP Morgan Overweight
2018-02-08 Eingeleitet RBC Capital Mkts Outperform
2017-12-15 Eingeleitet Canaccord Genuity Buy
2017-11-08 Hochstufung SunTrust Hold → Buy
2017-09-07 Hochstufung Piper Jaffray Neutral → Overweight
2017-08-30 Hochstufung Ladenburg Thalmann Neutral → Buy
2017-08-24 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2017-08-23 Hochstufung Leerink Partners Mkt Perform → Outperform
2017-05-02 Herabstufung Ladenburg Thalmann Buy → Neutral
2017-05-02 Herabstufung Leerink Partners Outperform → Mkt Perform
2017-05-01 Herabstufung Piper Jaffray Overweight → Neutral
2016-12-16 Eingeleitet Cantor Fitzgerald Overweight
2016-09-29 Bestätigt RBC Capital Mkts Outperform
2016-09-29 Herabstufung SunTrust Buy → Neutral
Alle ansehen

Intra Cellular Therapies Inc Aktie (ITCI) Neueste Nachrichten

pulisher
Feb 11, 2025

Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

abrdn plc Has $19.13 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Feb 11, 2025
pulisher
Feb 09, 2025

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock Holdings Lessened by Calamos Advisors LLC - MarketBeat

Feb 09, 2025
pulisher
Feb 06, 2025

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Sees Significant Growth in Short Interest - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

UBS Adjusts Price Target on Intra-Cellular Therapies to $132 From $87, Maintains Neutral Rating - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

Intra-Cellular Therapies (NASDAQ:ITCI) Downgraded by Canaccord Genuity Group to Hold - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders - GlobeNewswire Inc.

Feb 04, 2025
pulisher
Feb 04, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

KBC Group NV Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World

Feb 04, 2025
pulisher
Feb 04, 2025

StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI) - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Short Interest Up 5.3% in January - Defense World

Feb 04, 2025
pulisher
Feb 03, 2025

Canaccord cuts Intra-Cellular stock rating, raises target to $132 - MSN

Feb 03, 2025
pulisher
Feb 03, 2025

Intra-Cellular Therapies (NASDAQ:ITCI) Cut to “Hold” at Canaccord Genuity Group - Defense World

Feb 03, 2025
pulisher
Feb 02, 2025

Moody Aldrich Partners LLC Cuts Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Feb 02, 2025
pulisher
Feb 02, 2025

R Squared Ltd Takes $205,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Feb 02, 2025
pulisher
Feb 01, 2025

SG Americas Securities LLC Grows Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

Canaccord Genuity Downgrades Intra-Cellular Therapies to Hold From Buy, Adjusts Price Target to $132 From $119 - Marketscreener.com

Jan 31, 2025
pulisher
Jan 29, 2025

SG Americas Securities LLC Buys 8,673 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Defense World

Jan 29, 2025
pulisher
Jan 27, 2025

Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

Merit Financial Group LLC Buys New Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat

Jan 27, 2025
pulisher
Jan 26, 2025

(ITCI) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Jan 26, 2025
pulisher
Jan 24, 2025

Why Intra-Cellular Therapies, Inc. (ITCI) Is Skyrocketing Now - MSN

Jan 24, 2025

Finanzdaten der Intra Cellular Therapies Inc-Aktie (ITCI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Intra Cellular Therapies Inc-Aktie (ITCI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Mates Sharon
Chairman and CEO
Dec 04 '24
Option Exercise
12.73
51,000
649,230
1,121,329
Mates Sharon
Chairman and CEO
Dec 04 '24
Sale
85.80
51,000
4,375,659
1,070,329
Mates Sharon
Chairman and CEO
Dec 05 '24
Sale
84.08
51,697
4,346,842
1,070,329
$10.61
price down icon 0.09%
$116.85
price down icon 1.65%
$16.59
price down icon 1.31%
$81.92
price down icon 5.74%
$11.41
price down icon 0.61%
Kapitalisierung:     |  Volumen (24h):